{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:08:09Z","timestamp":1791644889689,"version":"4.3.4"},"reference-count":93,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The lack of clinical breakpoints and epidemiological cut-off values (ECOFFs) for antifungals prescribed for vulvovaginal candidiasis (VVC) make interpretation of antifungal susceptibility data difficult. This leads to empirical prescribing, poor clinical management and emergence of resistance. The\n                      <jats:italic>in vitro<\/jats:italic>\n                      susceptibilities of 152\n                      <jats:italic>Candida albicans<\/jats:italic>\n                      , 105\n                      <jats:italic>Candida parapsilosis<\/jats:italic>\n                      , 31\n                      <jats:italic>Nakaseomyces glabratus,<\/jats:italic>\n                      and 8\n                      <jats:italic>Pichia kudriavzevii<\/jats:italic>\n                      VVC isolates against eight antifungals, were determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.4. The minimum inhibitory concentration (MIC) distributions were analyzed and local ECOFFs were determined visually and statistically. The\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity of azoles was correlated with fluconazole susceptibility and clinical data were evaluated. The MICs of various azoles showed a significant correlation with the MICs of fluconazole and fluconazole non-wild type (WT) isolates had significantly higher MICs for other azoles. The estimated local ECOFFs for\n                      <jats:italic>C. albicans<\/jats:italic>\n                      were 0.016 mg\/L (ketoconazole, clotrimazole), 0.06 mg\/L (miconazole, econazole, itraconazole), 1 mg\/L (fenticonazole), and 3,200 mg\/L (boric acid). For\n                      <jats:italic>C. parapsilosis<\/jats:italic>\n                      , local ECOFFs were 0.06 mg\/L (ketoconazole, clotrimazole, itraconazole), 1 mg\/L (miconazole, econazole), 2 mg\/L (fenticonazole), and 3,200 mg\/L (boric acid). For\n                      <jats:italic>N. glabratus<\/jats:italic>\n                      , they were 1 mg\/L (ketoconazole, clotrimazole, miconazole, itraconazole), 2 mg\/L (econazole, fenticonazole), and 12,800 mg\/L (boric acid). Non-WT isolates were detected for azoles in\n                      <jats:italic>N. glabratus<\/jats:italic>\n                      (10%\u201335%),\n                      <jats:italic>C. albicans<\/jats:italic>\n                      (5%\u201316%), and\n                      <jats:italic>C. parapsilosis<\/jats:italic>\n                      (\u2264 3%). All isolates were WT for boric acid. Local ECOFFs were established for three major\n                      <jats:italic>Candida<\/jats:italic>\n                      species causing VVC, guiding the identification of non-WT isolates potentially associated with treatment failure.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        The interpretation of\n                        <jats:italic>in vitro<\/jats:italic>\n                        susceptibility data of\n                        <jats:italic>Candida<\/jats:italic>\n                        isolates from women with vulvovaginal candidiasis (VVC) is challenging due to the lack of clinical breakpoints (CBPs) and epidemiological cut-off values (ECOFFs) for drugs used in VVC. In the present study, local ECOFFs were established for three major\n                        <jats:italic>Candida<\/jats:italic>\n                        species causing VVC, guiding the identification of non-wild type isolates potentially associated with treatment failure. This paper provides the framework for developing ECOFFs and ultimately CBPs that would help guide antifungal therapy of VVC.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.02488-24","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:00:49Z","timestamp":1737622849000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Antifungal susceptibility testing and determination of local epidemiological cut-off values for\n                    <i>Candida<\/i>\n                    species isolated from women with vulvovaginal candidiasis"],"prefix":"10.1128","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7453-9489","authenticated-orcid":false,"given":"Vasiliki","family":"Kroustali","sequence":"first","affiliation":[{"name":"Clinical Microbiology Laboratory, \u201cAttikon\u201d University General Hospital, Medical School, National and Kapodistrian University of Athens","place":["Athens, Greece"]},{"name":"Molecular Microbiology and Immunology Laboratory, Department of Biomedical Sciences, University of West Attica","place":["Athens, Greece"]},{"name":"\u201cMycoLab\u201d, Diagnostic Laboratory of Sexually Transmitted Diseases, Specific Infectious Diseases, Fungal, Microbiological and Cytologic Examinations","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamprini","family":"Kanioura","sequence":"additional","affiliation":[{"name":"\u201cMycoLab\u201d, Diagnostic Laboratory of Sexually Transmitted Diseases, Specific Infectious Diseases, Fungal, Microbiological and Cytologic Examinations","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"Resoulai","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, \u201cAttikon\u201d University General Hospital, Medical School, National and Kapodistrian University of Athens","place":["Athens, Greece"]},{"name":"Molecular Microbiology and Immunology Laboratory, Department of Biomedical Sciences, University of West Attica","place":["Athens, Greece"]},{"name":"\u201cMycoLab\u201d, Diagnostic Laboratory of Sexually Transmitted Diseases, Specific Infectious Diseases, Fungal, Microbiological and Cytologic Examinations","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-1007","authenticated-orcid":false,"given":"Maria","family":"Siopi","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, \u201cAttikon\u201d University General Hospital, Medical School, National and Kapodistrian University of Athens","place":["Athens, Greece"]},{"name":"Molecular Microbiology and Immunology Laboratory, Department of Biomedical Sciences, University of West Attica","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Antonopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, General Hospital \"G. Gennimatas\"","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1509","authenticated-orcid":true,"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, \u201cAttikon\u201d University General Hospital, Medical School, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6010027"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13248"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30103-8"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof4040121"},{"key":"e_1_3_1_6_2","unstructured":"CDC \u2013 National Center for Health Statistics. Vulvovaginal candidiasis - STI treatment guidelines. Available from: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/candidiasis.htm. Retrieved 27 Apr 2024."},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.02.024"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/20503121221115201"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1476490"},{"key":"e_1_3_1_10_2","unstructured":"EUCAST Definitive Document E.Def 7.4 Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. 2023. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Files\/EUCAST_E.Def_7.4_Yeast_definitive_revised_2023.pdf. Retrieved 28 Jul 2024."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa260"},{"key":"e_1_3_1_12_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Overview of antifungal ECOFFs and clinical breakpoints for yeasts moulds and dermatophytes using the EUCAST E.Def 7.4 E.Def 9.4 and E.Def 11.0 proceduress. Version 40. 2023. Available from: http:\/\/www.eucast.org. Retrieved 27 Apr 2024."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.934353"},{"key":"e_1_3_1_14_2","unstructured":"EUCAST breakpoints for topical agents. Version 40. 2022. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_documents\/Topicals_guidance_note_220412.pdf. Retrieved 13 May 2024."},{"key":"e_1_3_1_15_2","volume-title":"Clinical laboratory testing and in vitro diagnosis test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility devices - part 1: Reference method for testing the in vitro activity of antimicrobials. Geneva, Switzerland","author":"ISO","year":"2006","unstructured":"ISO. 2006. Clinical laboratory testing and in vitro diagnosis test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility devices - part 1: Reference method for testing the in vitro activity of antimicrobials. Geneva, Switzerland"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02372-16"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01166.x"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.02.006"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01413-08"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.14744\/etd.2022.78910"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1469"},{"key":"e_1_3_1_23_2","first-page":"893","article-title":"Boric acid treatment of vulvovaginal candidiasis","volume":"43","author":"Swate TE","year":"1974","unstructured":"Swate TE, Weed JC. 1974. Boric acid treatment of vulvovaginal candidiasis. Obstet Gynecol 43:893\u2013895.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90347-x"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.111938"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31827307b2"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000126"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.649"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1067\/s0002-9378(03)00726-9"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)32581-9"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10647440400025603"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000733"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(02)00233-6"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000371759"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200607000-00010"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myv017"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2004.00970.x"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199507000-00005"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.1.89"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2009.02262.x"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904x18018"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00778-23"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2004.01023.x"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.3.336"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828x.1991.tb02798.x"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999009110479"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.03.017"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058601400604"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058901700410"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000473"},{"key":"e_1_3_1_51_2","first-page":"314","article-title":"Econazole nitrate in the treatment of candidal vaginitis","volume":"58","author":"Bloch B","year":"1980","unstructured":"Bloch B, Kretzel A. 1980. Econazole nitrate in the treatment of candidal vaginitis. S Afr Med J 58:314\u2013316.","journal-title":"S Afr Med J"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058701500508"},{"key":"e_1_3_1_53_2","first-page":"89","article-title":"Short-course treatment of vulvovaginal candidiasis: comparative study of fluconazole and intra-vaginal fenticonazole","volume":"64","author":"Murina F","year":"2012","unstructured":"Murina F, Graziottin A, Felice R, Di Francesco S, Mantegazza V. 2012. Short-course treatment of vulvovaginal candidiasis: comparative study of fluconazole and intra-vaginal fenticonazole. Minerva Ginecol 64:89\u201394.","journal-title":"Minerva Ginecol"},{"key":"e_1_3_1_54_2","first-page":"517","article-title":"Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole","volume":"39","author":"Sobel JD","year":"1994","unstructured":"Sobel JD, Schmitt C, Stein G, Mummaw N, Christensen S, Meriwether C. 1994. Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. J Reprod Med 39:517\u2013520.","journal-title":"J Reprod Med"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-002-0368-6"},{"key":"e_1_3_1_56_2","first-page":"662","article-title":"Treatment of vulvovaginal candidiasis with a 500-mg vaginal tablet of clotrimazole","volume":"6","author":"Hughes D","year":"1984","unstructured":"Hughes D, Kriedman T. 1984. Treatment of vulvovaginal candidiasis with a 500-mg vaginal tablet of clotrimazole. Clin Ther 6:662\u2013668.","journal-title":"Clin Ther"},{"key":"e_1_3_1_57_2","first-page":"148","article-title":"Single-dose 500-mg clotrimazole vaginal tablets compared with placebo in the treatment of Candida vaginitis","volume":"31","author":"Bro F","year":"1990","unstructured":"Bro F. 1990. Single-dose 500-mg clotrimazole vaginal tablets compared with placebo in the treatment of Candida vaginitis. J Fam Pract 31:148\u2013152.","journal-title":"J Fam Pract"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.2.179"},{"key":"e_1_3_1_59_2","first-page":"59","article-title":"Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis","volume":"70","author":"Reyes M","year":"2002","unstructured":"Reyes M, Villanueva Reynoso C, Ramos CJ, Men\u00e9ndez V\u00e1zquez J, Bail\u00f3n Uriza R, Vargas AJ. 2002. Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis. Ginecol Obstet Mex 70:59\u201365.","journal-title":"Ginecol Obstet Mex"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(00)00348-9"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016348309156251"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.03.005"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12602-022-09997-3"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02441-10"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.03.004"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.2155-2162.2005"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10091142"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10482-023-01914-0"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01459-20"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02693-18"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn486"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165376"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1995.tb09895.x"},{"key":"e_1_3_1_74_2","first-page":"18","article-title":"Combined single-day treatment in acute vulvovaginal candidosis","volume":"48","author":"Kovachev S","year":"2009","unstructured":"Kovachev S, Nacheva A, Vacheva-Dobrevska R, Vasilev N. 2009. Combined single-day treatment in acute vulvovaginal candidosis. Akush Ginekol (Mosk) 48:18\u201323.","journal-title":"Akush Ginekol (Mosk)"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.18502\/cmm.7.3.7801"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2017\/23578.9475"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040743"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/neq029"},{"key":"e_1_3_1_79_2","first-page":"57","article-title":"Antifungal resistance in Candida species isolated from patients presenting with vulvovaginal candidiasis during different trimesters of pregnancy","volume":"31","author":"Zaman R","year":"2024","unstructured":"Zaman R, Ullah I, Arif A. 2024. Antifungal resistance in Candida species isolated from patients presenting with vulvovaginal candidiasis during different trimesters of pregnancy. J Popul Ther Clin Pharmacol 31:57\u201365.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44259-023-00007-2"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01819-2"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02406-21"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2010.2708"},{"key":"e_1_3_1_84_2","doi-asserted-by":"publisher","DOI":"10.1086\/343826"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-07"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01072-18"},{"key":"e_1_3_1_87_2","first-page":"104882","article-title":"Evaluation of fluconazole, itraconazole, and voriconazole activity on Candida albicans: a case control study","volume":"84","author":"Dewi A","year":"2022","unstructured":"Dewi A, Langit Partha S, Dwi A, Widodo W, Dwi Endraswari P. 2022. Evaluation of fluconazole, itraconazole, and voriconazole activity on Candida albicans: a case control study. Ann Med Surg (Lond) 84:104882.","journal-title":"Ann Med Surg (Lond)"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.5.909"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1989.tb02296.x"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(86)90109-7"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2004.06.002"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.57.6.400"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2023.100162"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02366-21"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02488-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02488-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:09:31Z","timestamp":1741079371000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02488-24"}},"subtitle":[],"editor":[{"given":"Renato","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1128\/spectrum.02488-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02488-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"2024-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02488-24"}}